Coronary-Artery Bypass Surgery in Patients with Left Ventricular Dysfunction
2011
Аутори
Velazquez, Eric J.Lee, Kerry L.
Deja, Marek A.
Jain, Anil
Sopko, George
Marchenko, Andrey
Ali, Imtiaz S.
Pohost, Gerald
Gradinac, Sinisa
Abraham, William T.
Yii, Michael
Prabhakaran, Dorairaj
Szwed, Hanna
Ferrazzi, Paolo
Petrie, Mark C.
O'Connor, Christopher M.
Panchavinnin, Pradit
She, Lilin
Bonow, Robert O.
Rankin, Gena Roush
Jones, Robert H.
Rouleau, Jean-Lucien
STICH Investigators
Чланак у часопису
Метаподаци
Приказ свих података о документуАпстракт
BACKGROUND The role of coronary-artery bypass grafting (CABG) in the treatment of patients with coronary artery disease and heart failure has not been clearly established. METHODS Between July 2002 and May 2007, a total of 1212 patients with an ejection fraction of 35% or less and coronary artery disease amenable to CABG were randomly assigned to medical therapy alone (602 patients) or medical therapy plus CABG (610 patients). The primary outcome was the rate of death from any cause. Major secondary outcomes included the rates of death from cardiovascular causes and of death from any cause or hospitalization for cardiovascular causes. RESULTS The primary outcome occurred in 244 patients (41%) in the medical-therapy group and 218 (36%) in the CABG group (hazard ratio with CABG, 0.86; 95% confidence interval [CI], 0.72 to 1.04; P = 0.12). A total of 201 patients (33%) in the medical-therapy group and 168 (28%) in the CABG group died from an adjudicated cardiovascular cause (hazard ratio ...with CABG, 0.81; 95% CI, 0.66 to 1.00; P = 0.05). Death from any cause or hospitalization for cardiovascular causes occurred in 411 patients (68%) in the medical-therapy group and 351 (58%) in the CABG group (hazard ratio with CABG, 0.74; 95% CI, 0.64 to 0.85; P LT 0.001). By the end of the follow-up period (median, 56 months), 100 patients in the medical-therapy group (17%) underwent CABG, and 555 patients in the CABG group (91%) underwent CABG. CONCLUSIONS In this randomized trial, there was no significant difference between medical therapy alone and medical therapy plus CABG with respect to the primary end point of death from any cause. Patients assigned to CABG, as compared with those assigned to medical therapy alone, had lower rates of death from cardiovascular causes and of death from any cause or hospitalization for cardiovascular causes.
Извор:
New England Journal of Medicine, 2011, 364, 17, 1607-1616Финансирање / пројекти:
- National Heart, Lung, and Blood Institute [U01HL69015, U01HL69013], Abbott Laboratories, Novartis, Gilead, Boehringer Ingelheim Pharmaceuticals, Medtronic, St. Jude Medical, Biotronik, CardioMEMS
DOI: 10.1056/NEJMoa1100356
ISSN: 0028-4793
PubMed: 21463150
WoS: 000289940400007
Scopus: 2-s2.0-79955494359
Колекције
Институција/група
VinčaTY - JOUR AU - Velazquez, Eric J. AU - Lee, Kerry L. AU - Deja, Marek A. AU - Jain, Anil AU - Sopko, George AU - Marchenko, Andrey AU - Ali, Imtiaz S. AU - Pohost, Gerald AU - Gradinac, Sinisa AU - Abraham, William T. AU - Yii, Michael AU - Prabhakaran, Dorairaj AU - Szwed, Hanna AU - Ferrazzi, Paolo AU - Petrie, Mark C. AU - O'Connor, Christopher M. AU - Panchavinnin, Pradit AU - She, Lilin AU - Bonow, Robert O. AU - Rankin, Gena Roush AU - Jones, Robert H. AU - Rouleau, Jean-Lucien AU - STICH Investigators PY - 2011 UR - https://vinar.vin.bg.ac.rs/handle/123456789/4287 AB - BACKGROUND The role of coronary-artery bypass grafting (CABG) in the treatment of patients with coronary artery disease and heart failure has not been clearly established. METHODS Between July 2002 and May 2007, a total of 1212 patients with an ejection fraction of 35% or less and coronary artery disease amenable to CABG were randomly assigned to medical therapy alone (602 patients) or medical therapy plus CABG (610 patients). The primary outcome was the rate of death from any cause. Major secondary outcomes included the rates of death from cardiovascular causes and of death from any cause or hospitalization for cardiovascular causes. RESULTS The primary outcome occurred in 244 patients (41%) in the medical-therapy group and 218 (36%) in the CABG group (hazard ratio with CABG, 0.86; 95% confidence interval [CI], 0.72 to 1.04; P = 0.12). A total of 201 patients (33%) in the medical-therapy group and 168 (28%) in the CABG group died from an adjudicated cardiovascular cause (hazard ratio with CABG, 0.81; 95% CI, 0.66 to 1.00; P = 0.05). Death from any cause or hospitalization for cardiovascular causes occurred in 411 patients (68%) in the medical-therapy group and 351 (58%) in the CABG group (hazard ratio with CABG, 0.74; 95% CI, 0.64 to 0.85; P LT 0.001). By the end of the follow-up period (median, 56 months), 100 patients in the medical-therapy group (17%) underwent CABG, and 555 patients in the CABG group (91%) underwent CABG. CONCLUSIONS In this randomized trial, there was no significant difference between medical therapy alone and medical therapy plus CABG with respect to the primary end point of death from any cause. Patients assigned to CABG, as compared with those assigned to medical therapy alone, had lower rates of death from cardiovascular causes and of death from any cause or hospitalization for cardiovascular causes. T2 - New England Journal of Medicine T1 - Coronary-Artery Bypass Surgery in Patients with Left Ventricular Dysfunction VL - 364 IS - 17 SP - 1607 EP - 1616 DO - 10.1056/NEJMoa1100356 ER -
@article{ author = "Velazquez, Eric J. and Lee, Kerry L. and Deja, Marek A. and Jain, Anil and Sopko, George and Marchenko, Andrey and Ali, Imtiaz S. and Pohost, Gerald and Gradinac, Sinisa and Abraham, William T. and Yii, Michael and Prabhakaran, Dorairaj and Szwed, Hanna and Ferrazzi, Paolo and Petrie, Mark C. and O'Connor, Christopher M. and Panchavinnin, Pradit and She, Lilin and Bonow, Robert O. and Rankin, Gena Roush and Jones, Robert H. and Rouleau, Jean-Lucien and STICH Investigators", year = "2011", abstract = "BACKGROUND The role of coronary-artery bypass grafting (CABG) in the treatment of patients with coronary artery disease and heart failure has not been clearly established. METHODS Between July 2002 and May 2007, a total of 1212 patients with an ejection fraction of 35% or less and coronary artery disease amenable to CABG were randomly assigned to medical therapy alone (602 patients) or medical therapy plus CABG (610 patients). The primary outcome was the rate of death from any cause. Major secondary outcomes included the rates of death from cardiovascular causes and of death from any cause or hospitalization for cardiovascular causes. RESULTS The primary outcome occurred in 244 patients (41%) in the medical-therapy group and 218 (36%) in the CABG group (hazard ratio with CABG, 0.86; 95% confidence interval [CI], 0.72 to 1.04; P = 0.12). A total of 201 patients (33%) in the medical-therapy group and 168 (28%) in the CABG group died from an adjudicated cardiovascular cause (hazard ratio with CABG, 0.81; 95% CI, 0.66 to 1.00; P = 0.05). Death from any cause or hospitalization for cardiovascular causes occurred in 411 patients (68%) in the medical-therapy group and 351 (58%) in the CABG group (hazard ratio with CABG, 0.74; 95% CI, 0.64 to 0.85; P LT 0.001). By the end of the follow-up period (median, 56 months), 100 patients in the medical-therapy group (17%) underwent CABG, and 555 patients in the CABG group (91%) underwent CABG. CONCLUSIONS In this randomized trial, there was no significant difference between medical therapy alone and medical therapy plus CABG with respect to the primary end point of death from any cause. Patients assigned to CABG, as compared with those assigned to medical therapy alone, had lower rates of death from cardiovascular causes and of death from any cause or hospitalization for cardiovascular causes.", journal = "New England Journal of Medicine", title = "Coronary-Artery Bypass Surgery in Patients with Left Ventricular Dysfunction", volume = "364", number = "17", pages = "1607-1616", doi = "10.1056/NEJMoa1100356" }
Velazquez, E. J., Lee, K. L., Deja, M. A., Jain, A., Sopko, G., Marchenko, A., Ali, I. S., Pohost, G., Gradinac, S., Abraham, W. T., Yii, M., Prabhakaran, D., Szwed, H., Ferrazzi, P., Petrie, M. C., O'Connor, C. M., Panchavinnin, P., She, L., Bonow, R. O., Rankin, G. R., Jones, R. H., Rouleau, J.,& STICH Investigators. (2011). Coronary-Artery Bypass Surgery in Patients with Left Ventricular Dysfunction. in New England Journal of Medicine, 364(17), 1607-1616. https://doi.org/10.1056/NEJMoa1100356
Velazquez EJ, Lee KL, Deja MA, Jain A, Sopko G, Marchenko A, Ali IS, Pohost G, Gradinac S, Abraham WT, Yii M, Prabhakaran D, Szwed H, Ferrazzi P, Petrie MC, O'Connor CM, Panchavinnin P, She L, Bonow RO, Rankin GR, Jones RH, Rouleau J, STICH Investigators. Coronary-Artery Bypass Surgery in Patients with Left Ventricular Dysfunction. in New England Journal of Medicine. 2011;364(17):1607-1616. doi:10.1056/NEJMoa1100356 .
Velazquez, Eric J., Lee, Kerry L., Deja, Marek A., Jain, Anil, Sopko, George, Marchenko, Andrey, Ali, Imtiaz S., Pohost, Gerald, Gradinac, Sinisa, Abraham, William T., Yii, Michael, Prabhakaran, Dorairaj, Szwed, Hanna, Ferrazzi, Paolo, Petrie, Mark C., O'Connor, Christopher M., Panchavinnin, Pradit, She, Lilin, Bonow, Robert O., Rankin, Gena Roush, Jones, Robert H., Rouleau, Jean-Lucien, STICH Investigators, "Coronary-Artery Bypass Surgery in Patients with Left Ventricular Dysfunction" in New England Journal of Medicine, 364, no. 17 (2011):1607-1616, https://doi.org/10.1056/NEJMoa1100356 . .